YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance.

ABSTRACT:

Objective

Gastric cancer (GC) stands as a prevalent and deadly global malignancy. Despite its role as a preoperative neoadjuvant therapy, Apatinib's effectiveness is curtailed among GC patients exhibiting elevated YY1 expression. YY1's connection to adverse prognosis, drug resistance, and GC metastasis is established, yet the precise underlying mechanisms remain elusive. This study aims to unravel potential pathogenic pathways attributed to YY1.

Design

Utilizing bioinformatics analysis, we conducted differentially expressed genes, functional annotation, and pathway enrichment analyses, and further validation through cellular and animal experiments.

Results

Higher YY1 expression correlated with diminished postoperative progression-free survival (PFS) and disease-specif

SUBMITTER: Geng ZH 

PROVIDER: S-EPMC10863212 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature